9+ hour, 48+ min ago  (1273+ words) BBN Times Sir Pascal Soriot: Veterinary Scientist, Pharmaceutical Transformer, and Executive Director and CEO of Astra Zeneca Sir Pascal Soriot is one of the most consequential pharmaceutical executives in history. He is a French-born Australian businessman who took over a…...

4+ hour, 36+ min ago  (51+ words) open PR. com Precision and Customization: Revolutionizing Textile Design with CO2 Laser Technology Press release from: ABNewswire Permanent link to this press release: You can edit or delete your press release Precision and Customization: Revolutionizing Textile Design with CO2 Laser Technology here...

9+ hour, 28+ min ago  (285+ words) In today's seed sector, speed is a critical competitive advantage. Chile is increasingly positioning itself as a key facilitator in that race. At World Seed Congress 2026 in Lisbon, ANPROS Executive Director, Mario Schindler, and Executive Manager, Basilio Rojas, spoke about…...

1+ hour, 42+ min ago  (527+ words) Vision Monday. com...

4+ hour, 31+ min ago  (287+ words) Through Supply Partners' national distribution network, the collaboration creates a direct connection between training and field application. Installers trained on Sungrow technology gain ongoing access to technical resources, support and product expertise to Australian homes and businesses. Joe Zhou, Vice…...

7+ hour, 18+ min ago  (146+ words) Pharma Dispatch This unique historical oddity says all we need to know about the institution Can anyone think of any government agency or advisory committee that has ever publicly opposed more investment in the programs they oversee, not least when…...

1+ week, 11+ hour ago  (760+ words) New study to assess Halneuron" pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA. .. Dogwood Therapeutics Announces Commencement of Halneuron" Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study New study…...

4+ day, 2+ hour ago  (1435+ words) The Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease did not meet its primary or secondary endpoints Based on data from the Phase. .. Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease - The Phase…...

2+ week, 4+ hour ago  (794+ words) Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for ne. .. a Tyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting Company…...

4+ day, 11+ hour ago  (159+ words) ASCO " American Society of Cancer Oncology Title: Preliminary Phase 1 Results of a MICA/B-targeted CAR T-cell Designed to Overcome Solid Tumor Escape Mechanisms and Avoid the Requirement for Conditioning Chemotherapy Poster Presentation Date / Time: Saturday, May 30th, 1: 30-4: 30 CT. EULAR - European Congress…...